Ignite Creation Date:
2024-05-06 @ 2:22 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02023359
Status:
COMPLETED
Last Update Posted:
2015-12-29
First Post:
2013-12-23
Brief Title:
Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor HR Positive Human Epidermal Growth Factor 2 HER2 - Metastatic Breast Cancer
Sponsor:
Novartis Healthcare AS
Organization:
Novartis
Study Overview
Official Title:
Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive HER 2-negative Advanced Breast Cancer
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An observational study in patients with advanced ER HER2 negative breast cancer who are treated with everolimus and exemestane in combination The objective of the study is to assess the safety pattern of everolimus in a real world setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None